Benzinga - During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
SL Green Realty Corp. (NYSE: SLG)
- Dividend Yield: 13.73%
- Morgan Stanley analyst Ronald Josey maintained an Equal-Weight rating and cut the price target from $35 to $21 on March 31, 2023. This analyst has an accuracy rate of 70%.
- Evercore ISI Group analyst Steve Sakwa maintained an In-Line rating and cut the price target from $38 to $33 on March 27, 2023. This analyst has an accuracy rate of 64%.
- Recent News: SL Green Realty reported a decline in Q1 EPS.
- Dividend Yield: 13.15%
- Truist Securities analyst Michael Lapides maintained a Hold rating and raised the price target from $8 to $9 on March 31, 2023. This analyst has an accuracy rate of 63%.
- Credit Suisse analyst Omotayo Okusanya reiterated a Neutral rating with a price target of $11 on March 7, 2023. This analyst has an accuracy rate of 61%.
- Recent News: Medical Properties Trust posted weaker-than-expected Q1 sales results.
- Dividend Yield: 10.53%
- Credit Suisse analyst Omotayo Okusanya maintai reiterated a Neutral rating with a price target of $13 on April 12, 2023. This analyst has an accuracy rate of 61%.
- Citigroup analyst Nicholas Joseph maintained a Neutral rating and cut the price target from $13 to $10.5 on March 28, 2023. This analyst has an accuracy rate of 63%.
- Recent News: Sabra Health Care REIT posted better-than-expected sales for its fourth quarter.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.